Medicines labeled for the same conditions
Alternatives to bevacizumab-maly
12 other medicines are given the same way (intravenous) and in the same FDA class as bevacizumab-maly or labeled mainly for the same use (colorectal cancer); 2 are in its class, vascular endothelial growth factor inhibitors: bevacizumab and aflibercept; the others include 2 programmed death receptor-1 blocking antibodies, 2 epidermal growth factor receptor antagonists and 1 platinum-based drug (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as bevacizumab-maly?
Colorectal cancer lists all 23 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Bevacizumab-malyvascular endothelial growth factor inhibitor | this medicine | none listed | n/a | No | No current entry |
| Bevacizumabvascular endothelial growth factor inhibitor · same class | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Afliberceptvascular endothelial growth factor inhibitor · same class | Colorectal cancer | none listed | n/a | No | No current entry |
| Oxaliplatinplatinum-based drug | Colorectal cancer | 17 labelers | n/a | Yes | A presentation being discontinued |
| Fluorouracilnucleoside metabolic inhibitor | Colorectal cancer | 12 labelers | n/a | Yes | No current entry |
| Irinotecantopoisomerase inhibitor | Colorectal cancer | 12 labelers | n/a | Yes | A presentation being discontinued |
| Levoleucovorinfolate analog | Colorectal cancer | 8 labelers | n/a | No | No current entry |
| Nivolumabprogrammed death receptor-1 blocking antibody | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Ipilimumabctla-4-directed blocking antibody | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Ramucirumabvascular endothelial growth factor receptor 2 antagonist | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Cetuximabepidermal growth factor receptor antagonist | Colorectal cancer | none listed | n/a | Yes | No current entry |
| Panitumumabepidermal growth factor receptor antagonist | Colorectal cancer | none listed | n/a | Yes | No current entry |
| Pembrolizumabprogrammed death receptor-1 blocking antibody | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Bevacizumab-maly: the full record
- label, generics, price, shortages, recalls